Carregant...
Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
The lead author with clinical stage I malignant pleural mesothelioma, epithelioid type, highly programmed cell death ligand 1 (PD-L1) positive, and BAP1 negative, experienced a prompt and exceptionally favorable response to pembrolizumab monotherapy. After cessation of treatment due to immune-relate...
Guardat en:
| Publicat a: | Case Rep Oncol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
S. Karger AG
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7772860/ https://ncbi.nlm.nih.gov/pubmed/33442373 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000512013 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|